- In February 2023, researchers published a study in the journal Translational Andrology and Urology, highlighting Lycopene (LYC) as a promising adjunctive treatment for epididymitis. The study revealed that LYC effectively reduces inflammation and oxidative stress by modulating the PI3K/AKT signaling pathway, enhancing antioxidant activity, and protecting against cellular apoptosis. This advancement points to a potential natural therapy that could complement conventional treatment approaches
- In February 2023, a case report in Frontiers in Public Health documented the first known instance of chronic epididymitis caused by the Lymphogranuloma Venereum (LGV) L2 strain of Chlamydia trachomatis in an HIV-negative heterosexual male. The patient responded positively to a targeted antibiotic regimen. This rare presentation highlights the need for clinicians to consider LGV in persistent epididymitis cases, even outside high-risk populations
